Madrigal Pharmaceuticals (MDGL) Total Current Liabilities (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Total Current Liabilities data on file, last reported at $338.3 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $338.3 million, up 102.26% year-over-year; the trailing twelve-month figure through Mar 2026 was $338.3 million (up 102.26% YoY), and the FY2025 annual result was $310.3 million, up 83.3% from the prior year.
• Total Current Liabilities advanced to $338.3 million in Q1 2026 per MDGL's latest filing, from $310.3 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $391.4 million in Q3 2025 and troughed at $76.6 million in Q1 2022.
• A 5-year average of $163.6 million and a median of $118.5 million in 2023 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2023 and 2025: Total Current Liabilities advanced 0.75% in 2023, then soared 120.08% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $115.9 million in 2022, then advanced by 2.29% to $118.5 million in 2023, then jumped by 42.79% to $169.3 million in 2024, then soared by 83.3% to $310.3 million in 2025, then rose by 9.01% to $338.3 million in 2026.
• Business Quant data shows MDGL's Total Current Liabilities at $338.3 million in Q1 2026, $310.3 million in Q4 2025, and $391.4 million in Q3 2025.